

**GOVERNMENT OF INDIA  
MINISTRY OF HEALTH AND FAMILY WELFARE  
DEPARTMENT OF HEALTH AND FAMILY WELFARE**

**LOK SABHA  
UNSTARRED QUESTION NO. 1699  
TO BE ANSWERED ON 11<sup>th</sup> FEBRUARY, 2022**

**GENERIC VERSION OF REMDESIVIR**

**1699. SHRI NATARAJAN P.R.:**

Will the Minister of **HEALTH AND FAMILY WELFARE** be pleased to state:

(a) whether a prominent Indian drug company has developed a generic version of Remdesivir an anti viral drug which has been showing efficacy in treating COVID-19, if so, the details thereof;

(b) whether the Government proposes to give approval for issue of compulsory licences to the manufacturers of generic version of Remdesivir, if so, the details thereof and, if not, the reasons therefor;

(c) whether the Government is exporting the Anti Viral Drugs Remdesivir of generic version to USA, if so, the details thereof and the number of doses exported as on date;

(d) whether the Government is aware that Remdesivir is being stocked by USA, if so, the details thereof and the reasons therefor; and

(e) the action taken/being taken to reduce export of Remdesivir drug to meet the domestic demand?

**ANSWER  
THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND  
FAMILY WELFARE  
(DR. BHARATI PRAVIN PAWAR)**

(a) to (e): Remdesivir is a patented drug, manufactured in India under voluntary licenses granted by patent holder Gilead Life Sciences US, to seven Indian Pharmaceutical companies.

As per information received from Directorate General of Foreign Trade (DGFT), export license has been given to 02 firms for export of 3600 vials remdesivir to the USA. Further, the export of Remdesivir is under restricted category.

As informed by Ministry of External Affairs, as per publicly available information, the US had bought large supplies of Remdesivir from US company Gilead in June-July 2020.

\*\*\*\*\*